Why the study?
Does intravenous domperidone cause cardiac arrhythmias in patients receiving platinum-containing chemotherapy?
Does intravenous domperidone cause cardiac arrhythmias in patients receiving platinum-containing chemotherapy?
Intravenous domperidone is associated with a high risk of severe cardiac arrhythmias in patients undergoing cytotoxic chemotherapy.
Caution advised with IV domperidone in chemotherapy; small cohort leaves causal risk open for confirmation.
Four patients receiving platinum-containing chemotherapy were treated with domperidone (20 mg) by slow intravenous injection followed by a continuous infusion for 24 h at a dose of 10 mg 24 h-1 kg-1. Cardiac monitoring and plasma potassium and domperidone concentration measurements were performed. Severe cardiac arrhythmias occurred in two patients. A control group of 14 patients treated with similar chemotherapy, without domperidone, also underwent cardiac and plasma potassium monitoring. No significant arrhythmias were seen. The electrophysiologic effects of domperidone are discussed. It is concluded that treatment with intravenous domperidone is associated with the occurrence of cardiac arrhythmias.
No takes yet. Share an insight, caveat, or question.
Osborne et al. (1985) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: